Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned an average recommendation of “Moderate Buy” from the twenty-three research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, twenty-one have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $118.0952.

A number of research firms have recently issued reports on KYMR. Morgan Stanley reissued an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Canaccord Genuity Group began coverage on Kymera Therapeutics in a research report on Wednesday, May 6th. They set a “buy” rating and a $106.00 price target on the stock. UBS Group increased their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Piper Sandler increased their price target on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st.

Insider Activity at Kymera Therapeutics

In related news, Director Elena Ridloff sold 3,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $87.00, for a total transaction of $261,000.00. Following the sale, the director owned 3,000 shares of the company’s stock, valued at $261,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bruce Booth sold 5,900 shares of the firm’s stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total value of $530,764.00. Following the sale, the director directly owned 5,641 shares in the company, valued at approximately $507,464.36. The trade was a 51.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 383,734 shares of company stock valued at $32,454,902 over the last 90 days. Company insiders own 15.98% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC boosted its position in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Kymera Therapeutics in the 4th quarter worth $63,000. Bessemer Group Inc. boosted its position in shares of Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after purchasing an additional 815 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its position in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares in the last quarter.

Kymera Therapeutics Stock Performance

KYMR opened at $82.21 on Wednesday. Kymera Therapeutics has a 12-month low of $28.06 and a 12-month high of $103.00. The business’s fifty day simple moving average is $83.58 and its 200-day simple moving average is $78.05. The company has a market capitalization of $6.76 billion, a price-to-earnings ratio of -23.03 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. During the same quarter in the prior year, the company earned ($0.82) EPS. The business’s revenue was up 55.5% compared to the same quarter last year. On average, equities research analysts predict that Kymera Therapeutics will post -3.34 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.